

**Table 3 Reasons for changing first-line therapy in the study sample: 348 patients aged  $\geq$  18 years with T2DM who were starting second-line glucose-lowering therapy, Lebanon, 2015-2019**

<b>Reason for changing first-line therapy</b>	<b>No. (%) of patients</b>
Lack of efficacy	315 (90.5)
Weight gain	27 (7.8)
Hypoglycaemic event	18 (5.2)
Side effect	9 (2.6)
Physician preference	7 (2.0)
Patient convenience/comfort	5 (1.4)
Developed acute disease	4 (1.1)
Affordability	2 (0.6)
Developed chronic disease	1 (0.3)